Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 19-087

Status

Not yet recruiting

Description

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. - Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment

Condition

  • Hematologic Malignancy
  • Leukemia
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
  • Lymphoma, Non-Hodgkin

Interventions

  • CAR-37 T cells

Phase

Phase 1

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Dose Limiting Toxicity
  • The occurrence of study related adverse events

Secondary Outcome:

  • Disease Specific Response
  • Overall Survival
  • Progression Free Survival

Enrollment

18

Study Start Date

February 24, 2020

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Marcela V. Maus, M.D.,Ph.D.

Source

Massachusetts General Hospital

Official title

A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies

Clinicaltrials.gov Identifier

NCT04136275

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.